CTOs on the Move

Innovate Biopharmaceuticals

www.innovatebiopharma.com

 
Innovate is a clinical stage biotechnology company developing novel medicines for gastroenterological disorders.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Innovate Biopharmaceuticals raised $21M on 01/30/2018

Similar Companies

Life Technologies

Life Technologies Corporation (Life Technologies) is a global life sciences company. The Company's systems, consumables and services enable scientific researchers and commercial markets to accelerate scientific exploration, to discoveries and developments that improve the quality of life. The Company's products are also used in forensics, food and water safety, animal health testing and other industrial applications.

Saneron CCEL Therapeutics

Saneron CCEL Therapeutics is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

3 Prime

3 Prime is a Aston, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tempest Therapeutics

Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.

Code Biotherapeutics

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our 3DNA delivery platform is poised to transform the field of genetic medicines, enabling targeted delivery of gene therapy, RNAi and other genetic modalities. Currently we are advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne`s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.